On June 12, 2025, Novo Nordisk announced plans to start late-stage trials of its obesity drug amycretin next year. This decision is based on feedback from regulatory authorities following the end of its mid-stage trials.
Amycretin, a novel GLP-1 and amylin receptor agonist, has a dual-mode action designed to suppress hunger. Its advancement into Phase III clinical development, following promising early-phase results showing up to 22% body weight loss, positions it as a key future growth driver.
This move underscores Novo Nordisk's commitment to expanding its portfolio of differentiated obesity treatments. The AMAZE program, encompassing subcutaneous and oral amycretin, is expected to further strengthen the company's competitive moat in metabolic health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.